Due to the heterogeneous accumulation of the CXCR4-targeted tracer and the small patient population, the [68Ga]Pentixafor study failed to clearly demonstrate its usefulness for cancer prediction, prognosis, or tumor grade of breast cancer. The gene discussed is CXCR4; the disease is breast cancer.